Consultation is now open for items listed on the March 2022 PBAC agenda.
The PBAC welcomes input from patients, carers, health professionals, consumer groups or organisations and members of the public on medicines submitted for PBAC consideration.
The PBAC considers these public consultation inputs when considering the clinical and economic evidence presented by the applicant.
Input can be submitted via the online survey which includes an option to upload a file.
You...More
Consultation is now open for applications that are anticipated to be considered by the Medical Services Advisory Committee (MSAC) on 31 March - 1 April 2022.
MSAC values consultation input from individuals and organisations with an interest in an application that it is considering, including experience of the medical conditions, services or technologies being addressed by the application.
It is anticipated that the below-mentioned applications will proceed to MSAC in March/April...More
Consultation is now open for applications that are anticipated to be considered by the PICO Advisory Sub-Committee (PASC) of the Medical Services Advisory Committee (MSAC) on 13-14 April 2022.
PASC values consultation input from individuals and organisations with an interest in an application that it is considering, including experience of the medical conditions, services or technologies being addressed by the application.
It is anticipated that the below-mentioned applications...More
PBAC Intracycle meetings are held between the main PBAC meetings. Submission items considered by the PBAC at these meetings typically relate to matters arising from previous submissions but can also relate to new medicines.
The PBAC welcomes input from patients, carers, health professionals, consumer groups or organisations and members of the public on medicines submitted for PBAC consideration.
All public consultation inputs are considered by the PBAC when...More
The Commonwealth has entered into a new Strategic Agreement in relation to reimbursement, health technology assessment (HTA) and other matters (the Agreement) with Medicines Australia acting on behalf of the innovator medicines industry. As agreed under Clause 5.2 of the Agreement, the Minister for Health has sought the advice of the Pharmaceutical Benefits Advisory Committee (PBAC) on whether the base case discount rate at 3A.1 of the PBAC guidelines aligns with international best...More
Consultation is now open for items listed on the July 2022 PBAC agenda.
The PBAC welcomes input from patients, carers, health professionals, consumer groups or organisations and members of the public on medicines submitted for PBAC consideration.
The PBAC considers these public consultation inputs when considering the clinical and economic evidence presented by the applicant.
Input can be submitted via the online survey. A copy of the questions asked in the survey can...More
The Commonwealth has entered into a new Strategic Agreement in relation to reimbursement, health technology assessment (HTA) and other matters (the Agreement) with Medicines Australia acting on behalf of the innovator medicines industry. As agreed under Clause 5.2 of the Agreement, advice was sought from the Pharmaceutical Benefits Advisory Committee (PBAC) on whether the base case discount rate at 3A.1 of the PBAC guidelines aligns with international best...More
Consultation is now open for applications that are anticipated to be considered by the Medical Services Advisory Committee (MSAC) on 28-29 July 2022.
MSAC values consultation input from individuals and organisations with an interest in an application that it is considering, including experience of the medical conditions, services or technologies being addressed by the application.
Consultation input must be received by no later than Friday, 10 June 2022 for it to be considered by...More
Consultation is now open for applications that are anticipated to be considered by the PICO Advisory Sub-Committee (PASC) of the Medical Services Advisory Committee (MSAC) on 11-12 August 2022.
PASC values consultation input from individuals and organisations with an interest in an application that it is considering, including experience of the medical conditions, services or technologies being addressed by the application.
It is anticipated that the below-mentioned applications...More
Consultation is now open for items listed on the November 2022 PBAC agenda.
The PBAC welcomes input from patients, carers, health professionals, consumer groups or organisations and members of the public on medicines submitted for PBAC consideration.
The PBAC considers these public consultation inputs when considering the clinical and economic evidence presented by the applicant.
Input can be submitted via the online survey. A copy of the questions asked in the survey...More
Consultation is now open for applications that are anticipated to be considered by the Medical Services Advisory Committee (MSAC) on
24-25 November 2022.
MSAC values consultation input from individuals and organisations with an interest in an application that it is considering, including experience of the medical conditions, services or technologies being addressed by the application.
Consultation input must be received by no later than Friday, 7 October 2022 for it to be...More
The Health Technology Assessment (HTA) Consumer Consultative Committee (CCC) is hosting its second Symposium “Conversations for Change” for health consumers and health consumer organisations with an interest in HTA.
Over two half-days, the Symposium will explore the evolving role of consumers in the HTA process.
Tuesday 18 October: 1.30pm – 5.30pm (AEDT), and
Wednesday 19 October: 10.30am – 2.30pm (AEDT) ...More
Consultation is now open for applications that are anticipated to be considered by the PICO Advisory Sub-Committee (PASC) of the Medical Services Advisory Committee (MSAC) on 8-9 December 2022.
PASC values consultation input from individuals and organisations with an interest in an application that it is considering, including experience of the medical conditions, services or technologies being addressed by the application.
It is anticipated that the below-mentioned applications...More
The views and experiences of patients (consumers) and their carers on medicines and medical services and products play an important part in informing advice to the Australian Government on what should be provided.
A process called health technology assessment (HTA) is used to inform this advice and includes consideration of the views and experiences of patients and carers.
The Office of Health Technology Assessment’s (OHTA) Consumer Evidence and Engagement Unit (CEEU) is looking...More
The views and experiences of patients (consumers) and their carers on medicines and medical services and products play an important part in informing advice to the Australian Government on what should be provided.
A process called health technology assessment (HTA) is used to inform this advice and includes consideration of the views and experiences of patients and carers.
The Office of Health Technology Assessment’s (OHTA) Consumer Evidence...More
Consultation is now open for applications that are anticipated to be considered by the Medical Services Advisory Committee (MSAC) on 30 - 31 March 2023.
MSAC values consultation input from individuals and organisations with an interest in an application that it is considering, including experience of the medical conditions, services or technologies being addressed by the application.
It is anticipated that the below-mentioned applications will proceed to MSAC in...More
Consultation is now open for applications that are anticipated to be considered by the PICO Advisory Sub-Committee (PASC) of the Medical Services Advisory Committee (MSAC) on 13-14 April 2023.
PASC values consultation input from individuals and organisations with an interest in an application that it is considering, including experience of the medical conditions, services or technologies being addressed by the application.
It is anticipated that the below-mentioned applications...More
Consultation has opened for the July 2023 Pharmaceutical Benefits Advisory Committee (PBAC) agenda.
The PBAC welcomes input from patients, carers, health professionals, consumer groups or organisations and members of the public on medicines submitted for PBAC consideration.
The PBAC considers these public consultation inputs when considering the clinical and economic evidence presented by the applicant.
How to provide input
Input can be submitted via the online...More
Consultation 1 is open until 6 June 2023 and is the first in a series of consultations.
Consultation 1 aims to gather evidence or examples in relation to the objectives of the HTA Review, not previously considered through other recent stakeholder consultation relating to HTA .
It seeks to allow a broad range of stakeholders to provide early input into the HTA Review, with a focus on assisting the Reference Committee, as set out in the terms of reference , to identify...More
Consultation is now open for applications that are anticipated to be considered by the Medical Services Advisory Committee (MSAC) on 27-28 July 2023
MSAC values consultation input from individuals and organisations with an interest in an application that it is considering, including experience of the medical conditions, services or technologies being addressed by the application.
It is anticipated that the below-mentioned applications will proceed to MSAC in July 2023....More
The 2022-2027 Strategic Agreement between the Commonwealth and Medicines Australia includes a commitment to the co-design of an Enhanced Consumer Engagement Process (clause 6.3.2).
The co-design aims to facilitate the capture of consumer and patient perspectives earlier in the health technology assessment (HTA) process to assist the Pharmaceutical Benefits Advisory Committee and other HTA advisory bodies to obtain an understanding of issues arising from new technologies, innovations...More
Expressions of interest for participating in a deep-dive with the Reference Committee for the HTA Review.
Throughout the review the Reference Committee would like to have direct discussions with stakeholders who have in-depth knowledge or understanding on topics or issues highly relevant to the review. These deep-dives will allow the Reference Committee to unpack the more complex topics to ensure the review is based on a thorough and nuanced understanding of the...More
Consultation has opened for the November 2023 Pharmaceutical Benefits Advisory Committee (PBAC) agenda.
The PBAC welcomes input from patients, carers, health professionals, consumer groups or organisations and members of the public on medicines submitted for PBAC consideration.
The PBAC considers these public consultation inputs when considering the clinical and economic evidence presented by the applicant.
How to provide input
Input can be submitted via the online...More
Consultation is now open for applications that are anticipated to be considered by the Medical Services Advisory Committee (MSAC) on 23-24 November 2023.
MSAC values consultation input from individuals and organisations with an interest in an application that it is considering, including experience of the medical conditions, services or technologies being addressed by the application.
It is anticipated that the below-mentioned applications will proceed to MSAC in July 2023....More
Consultation is now open for applications that are anticipated to be considered by the PICO Advisory Sub-Committee (PASC) of the Medical Services Advisory Committee (MSAC) on 7-8 December 2023.
PASC values consultation input from individuals and organisations with an interest in an application that it is considering, including experience of the medical conditions, services or technologies being addressed by the application.
It is anticipated that the below-mentioned applications...More
The Medical Services Advisory Committee (MSAC) has developed a Draft Framework for the MSAC assessment of radiopharmaceuticals.
The purpose of this Framework is to identify the supplementary information requirements to those set out in the Guidelines for preparing assessments for the Medical Services Advisory Committee (“MSAC Guidelines”) to ensure that radiopharmaceuticals to be used within the scope of a proposed MBS item descriptor in an application for a new or...More